Correlation Between 26443CAA1 and Lipocine
Specify exactly 2 symbols:
By analyzing existing cross correlation between DUKE UNIV HEALTH and Lipocine, you can compare the effects of market volatilities on 26443CAA1 and Lipocine and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 26443CAA1 with a short position of Lipocine. Check out your portfolio center. Please also check ongoing floating volatility patterns of 26443CAA1 and Lipocine.
Diversification Opportunities for 26443CAA1 and Lipocine
Very weak diversification
The 3 months correlation between 26443CAA1 and Lipocine is 0.5. Overlapping area represents the amount of risk that can be diversified away by holding DUKE UNIV HEALTH and Lipocine in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lipocine and 26443CAA1 is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on DUKE UNIV HEALTH are associated (or correlated) with Lipocine. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lipocine has no effect on the direction of 26443CAA1 i.e., 26443CAA1 and Lipocine go up and down completely randomly.
Pair Corralation between 26443CAA1 and Lipocine
Assuming the 90 days trading horizon DUKE UNIV HEALTH is expected to under-perform the Lipocine. But the bond apears to be less risky and, when comparing its historical volatility, DUKE UNIV HEALTH is 2.31 times less risky than Lipocine. The bond trades about -0.23 of its potential returns per unit of risk. The Lipocine is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest 515.00 in Lipocine on October 8, 2024 and sell it today you would lose (15.00) from holding Lipocine or give up 2.91% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 36.84% |
Values | Daily Returns |
DUKE UNIV HEALTH vs. Lipocine
Performance |
Timeline |
DUKE UNIV HEALTH |
Lipocine |
26443CAA1 and Lipocine Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with 26443CAA1 and Lipocine
The main advantage of trading using opposite 26443CAA1 and Lipocine positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 26443CAA1 position performs unexpectedly, Lipocine can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipocine will offset losses from the drop in Lipocine's long position.26443CAA1 vs. Delek Logistics Partners | 26443CAA1 vs. Sun Country Airlines | 26443CAA1 vs. United Airlines Holdings | 26443CAA1 vs. Noble plc |
Lipocine vs. Reviva Pharmaceuticals Holdings | Lipocine vs. ZyVersa Therapeutics | Lipocine vs. Unicycive Therapeutics | Lipocine vs. Checkpoint Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Complementary Tools
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |